Chiusura precedente | 0,8170 |
Aperto | 0,8060 |
Denaro | 0,7610 x N/D |
Lettera | 0,7770 x N/D |
Min-Max giorno | 0,8060 - 0,8060 |
Intervallo di 52 settimane | 0,7800 - 5,3600 |
Volume | |
Media Volume | 60 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | N/D |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Mainz Biomed team members will be available throughout the event at the Company’s booth located in Hall C, Stand C3-92BERKELEY, Calif. and MAINZ, Germany, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leading molecular genetics diagnostic company focused on early cancer detection, announced today its participation in the upcoming UEG Week. This prominent event, organized by the United European Gastroenterology and scheduled to take place in
BERKELEY, Calif. and MAINZ, Germany, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Bill Caragol, Chief Financial Officer, will attend the JonesTrading 2023 Healthcare Summit which will take place October 9-11, 2023 in Miami Beach, Florida. The Summit will be attended by key opinion leaders, healthcare focused institutional investors, a
Strategic Collaboration Elevates Early Cancer Detection, Bringing State-of-the-Art Diagnostic Capabilities to Romanian PopulationBERKELEY, Calif. and MAINZ, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the live launch of Mainz Biomed’s flagship product, ColoAlert® — a highly effective and user-friendly at-home detection test for colorecta